Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-Resistant Epilepsy Announced at 2024 Annual…

Posted: December 7, 2024 at 2:50 am

– SAFETY: NRTX-1001 has been well-tolerated to date at both high and low doses. No adverse events have been attributed to the cell therapy

Read more here:
Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-Resistant Epilepsy Announced at 2024 Annual...

Related Posts